The Technical Analyst
Vincerx Pharma, Inc. [VINC]
Exchange: Nasdaq Capital Market Industry: Biotechnology
Vincerx Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-9.66% $1.310
America/New_York / 3 feb 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 27.76 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Mar 27, 2023 |
| SharesOutstanding: | 21.19 mill |
| Avg Daily Volume: | 0.249 mill |
| RATING 2023-02-03 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 21.26 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE 0 | industry: PE 12.65 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$22.67 (1 630.74%) $21.36 |
| Date: 2023-02-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.217 - 1.403 ( +/- 7.10%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-12-14 | Thomas Tom C | Buy | 7 000 | Common Stock |
| 2022-12-14 | Hamdy Ahmed Md | Buy | 35 280 | Common Stock |
| 2022-12-14 | Izumi Raquel E. | Buy | 28 738 | Common Stock |
| 2022-11-15 | Seelenberger Alexander A. | Buy | 56 000 | Stock Option (right to buy) |
| 2022-11-15 | Izumi Raquel E. | Buy | 60 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 87.80 |
| Last 72 transactions |
| Buy: 13 397 659 | Sell: 1 616 942 |
Forecast:
16:00 - $1.320
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.320
Forecast 2: 16:00 - $1.320
Forecast 3: 16:00 - $1.320
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.310 (-9.66% ) |
| Volume | 0.0875 mill |
| Avg. Vol. | 0.249 mill |
| % of Avg. Vol | 35.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VINC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VINC
Latest Press Releases
2022-12-13 09:29:00 - Press Release
Vincerx Pharma Announces Fda Safe To Proceed Letter For Investigational New Drug (ind) Application For Its ΑvΒ3 Small Molecule-drug Conjugate (smdc) Vip236
Vip236 is a first-in-class Α v Β 3 integrin binder smdc with the potential to address a broad patient population across multiple solid tumor indications
2022-12-12 16:05:00 - Press Release
Vincerx Pharma Provides American Society Of Hematology Annual Meeting 2022 Poster Highlights On Enitociclib In Multiple Tumor Types
In a multiple myeloma (mm) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-mm agents
2022-12-11 10:05:00 - Press Release
Vincerx Pharma Presents Preclinical Data On Vip943 In Acute Myeloid Leukemia Models At The 64th American Society Of Hematology Annual Meeting 2022
Vincerx's proprietary payload and linker technology and vip943, a novel anti-cd123 antibody drug conjugate (adc), demonstrated superiority with significant improved safety in non-human primates (nhp) when compared with mylotarg™ (gemtuzumab ozogamicin)
2022-11-03 09:05:00 - Press Release
Vincerx Pharma Announces Upcoming Poster Presentations At The 64th American Society Of Hematology (ash) Annual Meeting 2022
Palo alto, calif., nov. 03, 2022 (globe newswire) -- vincerx pharma, inc. (nasdaq: vinc), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced three poster presentations at the upcoming 64th american society of hematology (ash) annual meeting 2022, being held virtually and in new orleans, louisiana from december 10-13, 2022.
2022-06-10 08:00:00 - Press Release
Vincerx Pharma Presents Preclinical And Clinical Data On Ptefb/cdk9 Inhibitor Vip152 In Lymphoma At The European Hematology Association 2022 Congress
Preclinical data demonstrate vip152 as the most selective cdk9 inhibitor compared with other cdk9 inhibitors, with the most robust myc mrna downregulation
Latest News
2022-06-07 14:19:10 - Benzinga
Analysts Cuts Price Target On This Small Cap But Remain Bullish
Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse.
2022-02-09 08:00:00 - GlobeNewsWire
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx's management team will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.
2021-09-16 07:30:00 - GlobeNewsWire
Vincerx Pharma Announces $50 Million Private Placement
Strengthened financial position extends expected cash runway into 2023 Strengthened financial position extends expected cash runway into 2023
2021-08-12 16:05:00 - GlobeNewsWire
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors
2021-07-08 17:37:41 - GuruFocus
4 Stocks With CEO Buys in the Past Month
According to the CEO Buys Screen, a Premium All-in-One Screener template, four stocks that had at least three insider buys including the CEO during the past month are REV Group Inc. ( REVG , Financial), Vincerx Pharma Inc. ( VINC , Financial), Core Molding Technologies Inc. ( CMT , Financial) and Processa Pharmaceuticals Inc. ( PCSA , Financial).
2021-06-04 08:00:00 - GlobeNewsWire
Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting
2021-06-03 16:05:00 - GlobeNewsWire
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors
First patient dosed by Vincerx marks significant milestone in Company's development First patient dosed by Vincerx marks significant milestone in Company's development
2021-05-17 08:00:00 - GlobeNewsWire
Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update
Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021
2021-04-20 08:00:00 - GlobeNewsWire
Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome
Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021
2021-04-10 08:31:00 - GlobeNewsWire
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models